Reuters logo
BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414
August 31, 2017 / 9:44 PM / 20 days ago

BRIEF-Aptevo Therapeutics and MorphoSys ends joint agreement to develop and commercialize MOR209/ES414

Aug 31 (Reuters) - Aptevo Therapeutics Inc

* Aptevo Therapeutics and MorphoSys end joint development and commercialization agreement for MOR209/ES414

* Aptevo Therapeutics Inc - ‍Aptevo regains worldwide rights to novel Bispecific Prostate Cancer Immunotherapeutic MOR209/ES414​

* Aptevo Therapeutics Inc - ‍Preliminary phase I data show markedly lower anti-drug antibody titers demonstrating effectiveness of new dosing regimen​

* Aptevo - End of partnership with MorphoSys AG for development, commercialization of treatment for metastatic castration resistant prostate cancer​ Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below